{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T11:50:26Z","timestamp":1791805826087,"version":"4.3.4"},"reference-count":31,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:00:00Z","timestamp":1708473600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Detection of bone marrow involvement (BMI) in diffuse large B-cell lymphoma (DLBCL) typically relies on invasive bone marrow biopsy (BMB) that faces procedure limitations, while\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT imaging offers a noninvasive alternative. The present study assesses the performance of\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT in DLBCL BMI detection, its agreement with BMB, and the impact of BMI on survival outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>\n                      This retrospective study analyzes baseline\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT and BMB findings in145 stage II\u2013IV DLBCL patients, evaluating both performance of the two diagnostic procedures and the impact of BMI on survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>DLBCL BMI was detected in 38 patients (26.2%) using PET\/CT and in 18 patients (12.4%) using BMB. Concordant results were seen in 79.3% of patients, with 20.7% showing discordant results. Combining PET\/CT and BMB data, we identified 29.7% of patients with BMI. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of PET\/CT for detecting DLBCL BMI were 88.4%, 100%, 100%, 95.3%, and 96.5%, respectively, while BMB showed lower sensitivity (41.9%) and NPV (46.8%). The median overall survival (OS) was not reached in any gender subgroup, with 5-year OS rates of 82% (total), 84% (female), and 80% (male) (p = 0.461), while different International Prognostic Index (IPI) groups exhibited varied 5-year OS rates: 94% for low risk (LR), 91% for low-intermediate risk (LIR), 84% for high-intermediate risk (HIR), and 65% for high risk (HR) (p = 0.0027). Bone marrow involvement did not impact OS significantly (p = 0.979).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      <jats:sup>18<\/jats:sup>\n                      F-FDG PET\/CT demonstrated superior diagnostic accuracy compared to BMB. While other studies reported poorer overall and BMI 5-year OS in DLBCL, our findings demonstrated favourable survival data.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2478\/raon-2024-0004","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T18:47:23Z","timestamp":1708454843000},"page":"15-22","source":"Crossref","is-referenced-by-count":6,"title":["Detection performance and prognostic value of initial bone marrow involvement in diffuse large B-cell lymphoma: a single centre\n                    <sup>18<\/sup>\n                    F-FDG PET\/CT and bone marrow biopsy evaluation study"],"prefix":"10.2478","volume":"58","author":[{"given":"Andrej","family":"Doma","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine , Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine , University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Zevnik","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine , Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine , University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Studen","sequence":"additional","affiliation":[{"name":"Experimental Particle Physics Department , Jo\u017eef Stefan Institute , Ljubljana , Slovenia"},{"name":"Faculty of Mathematics and Physics , University of Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronika Kloboves","family":"Prevodnik","sequence":"additional","affiliation":[{"name":"Department of Cytopathology , Institute of Oncology Ljubljana , Ljubljana , Slovenia"},{"name":"Faculty of Medicine , University of Maribor , Maribor , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gorana","family":"Gasljevic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine , University of Maribor , Maribor , Slovenia"},{"name":"Department of Pathology , Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Jezersek","family":"Novakovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine , University of Ljubljana , Ljubljana , Slovenia"},{"name":"Division of Medical Oncology , Institute of Oncology Ljubljana , Ljubljana , Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2024,2,21]]},"reference":[{"key":"2026071211371386754_j_raon-2024-0004_ref_001","doi-asserted-by":"crossref","unstructured":"Sehn LH, Salles G. Diffuse large B-cell lymphoma. N Engl J Med 2021; 384: 842\u201358. doi: 10.1056\/NEJMra2027612","DOI":"10.1056\/NEJMra2027612"},{"key":"2026071211371386754_j_raon-2024-0004_ref_002","doi-asserted-by":"crossref","unstructured":"Cheson BD, Ansell S, Schwartz L, Gordon LI, Advani R, Jacene HA, et al. Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 2016; 128: 2489\u201396. doi: 10.1182\/blood-2016-05-718528","DOI":"10.1182\/blood-2016-05-718528"},{"key":"2026071211371386754_j_raon-2024-0004_ref_003","doi-asserted-by":"crossref","unstructured":"Sehn LH, Scott DW, Chhanabhai M, Berry B, Ruskova A, Berkahn L, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 2011; 29: 1452\u20137. doi: 10.1200\/JCO.2010.33.3419","DOI":"10.1200\/JCO.2010.33.3419"},{"key":"2026071211371386754_j_raon-2024-0004_ref_004","doi-asserted-by":"crossref","unstructured":"Adams HJ, Nievelstein RA, Kwee TC. Opportunities and limitations of bone marrow biopsy and bone marrow FDG-PET in lymphoma. Blood Rev 2015; 29: 417\u201325. doi: 10.1016\/j.blre.2015.06.003","DOI":"10.1016\/j.blre.2015.06.003"},{"key":"2026071211371386754_j_raon-2024-0004_ref_005","doi-asserted-by":"crossref","unstructured":"Khan AB, Barrington SF, Mikhaeel NG, Hunt AA, Cameron L, Morris T, et al. PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood 2013; 122: 61\u20137. doi: 10.1182\/blood-2012-12-473389","DOI":"10.1182\/blood-2012-12-473389"},{"key":"2026071211371386754_j_raon-2024-0004_ref_006","doi-asserted-by":"crossref","unstructured":"Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059\u201368. doi: 10.1200\/JCO.2013.54.8800","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"2026071211371386754_j_raon-2024-0004_ref_007","doi-asserted-by":"crossref","unstructured":"Bain BJ. Bone marrow biopsy morbidity and mortality. Br J Haematol 2003; 121: 949\u201351. doi: 10.1046\/j.1365-2141.2003.04329.x","DOI":"10.1046\/j.1365-2141.2003.04329.x"},{"key":"2026071211371386754_j_raon-2024-0004_ref_008","doi-asserted-by":"crossref","unstructured":"Basu S, Alavi A. SPECT-CT and PET-CT in oncology \u2013 an overview. Curr Med Imaging Rev 2011; 7: 202\u20139. doi: 10.2174\/157340511796411168","DOI":"10.2174\/157340511796411168"},{"key":"2026071211371386754_j_raon-2024-0004_ref_009","doi-asserted-by":"crossref","unstructured":"Berthet L, Cochet A, Kanoun S, Berriolo-Riedinger A, Humbert O, Toubeau M, et al. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET\/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med 2013; 54: 1244\u201350. doi: 10.2967\/jnumed.112.114710","DOI":"10.2967\/jnumed.112.114710"},{"key":"2026071211371386754_j_raon-2024-0004_ref_010","doi-asserted-by":"crossref","unstructured":"El Karak F, Bou-Orm IR, Ghosn M, Kattan J, Farhat F, Ibrahim T, et al. PET\/CT scanner and bone marrow biopsy in detection of bone marrow involvement in diffuse large B-cell lymphoma. PLoS One 2017; 12: e0170299. doi: 10.1371\/journal.pone.0170299","DOI":"10.1371\/journal.pone.0170299"},{"key":"2026071211371386754_j_raon-2024-0004_ref_011","doi-asserted-by":"crossref","unstructured":"Hao B, Zhao L, Luo NN, Ruan D, Pang YZ, Guo W, et al. Is it sufficient to evaluate bone marrow involvement in newly diagnosed lymphomas using 18F-FDG PET\/CT and\/or routine iliac crest biopsy? A new approach of PET\/CT-guided targeted bone marrow biopsy. BMC Cancer 2018; 18: 1192. doi: 10.1186\/s12885-018-5104-0","DOI":"10.1186\/s12885-018-5104-0"},{"key":"2026071211371386754_j_raon-2024-0004_ref_012","doi-asserted-by":"crossref","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015; 42: 328\u201354. doi: 10.1007\/s00259-014-2961-x","DOI":"10.1007\/s00259-014-2961-x"},{"key":"2026071211371386754_j_raon-2024-0004_ref_013","doi-asserted-by":"crossref","unstructured":"Lee SH, Erber WN, Porwit A, Tomonaga M, Peterson LC. International Council for Standardization in hematology. ICSH guidelines for the standardization of bone marrow specimens and reports. Int J Lab Hematol 2008; 30: 349\u201364. doi: 10.1111\/j.1751-553X.2008.01100.x","DOI":"10.1111\/j.1751-553X.2008.01100.x"},{"key":"2026071211371386754_j_raon-2024-0004_ref_014","doi-asserted-by":"crossref","unstructured":"Brozic A, Pohar Marinsek Z, Novakovic S, Kloboves Prevodnik V. Inconclusive flow cytometric surface light chain results; can cytoplasmic light chains, Bcl-2 expression and PCR clonality analysis improve accuracy of cytological diagnoses in B-cell lymphomas? Diagn Pathol 2015; 10: 191. doi: 10.1186\/s13000-015-0427-5","DOI":"10.1186\/s13000-015-0427-5"},{"key":"2026071211371386754_j_raon-2024-0004_ref_015","unstructured":"Bro\u017ei\u010d A. [Clonality and antigenic properties of reactive and neoplastic lymphocytic proliferations]. [Slovenian]. [Doctoral dissertation]. Ljubljana: University of Ljubljana. [cited 2023 Jul 27]. Available at: https:\/\/repozitorij.uni-lj.si\/IzpisGradiva.php?lang=slv&id=84423"},{"key":"2026071211371386754_j_raon-2024-0004_ref_016","doi-asserted-by":"crossref","unstructured":"Salaun PY, Gastinne T, Bodet-Milin C, Campion L, Cambefort P, Moreau, et al. Analysis of 18F-FDG PET diffuse bone marrow uptake and splenic uptake in staging of Hodgkin\u2019s lymphoma: a reflection of disease infiltration or just inflammation? Eur J Nucl Med Mol Imaging 2009; 36: 1813\u201321. doi: 10.1007\/s00259-009-1183-0","DOI":"10.1007\/s00259-009-1183-0"},{"key":"2026071211371386754_j_raon-2024-0004_ref_017","doi-asserted-by":"crossref","unstructured":"Zwarthoed C, El-Galaly TC, Canepari M, Ouvrier MJ, Viotti J, Ettaiche M, et al. Prognostic value of bone marrow tracer uptake pattern in baseline PET scans in Hodgkin lymphoma: results from an International Collaborative Study. J Nucl Med 2017; 58: 1249\u201354. doi: 10.2967\/jnumed.116.184218","DOI":"10.2967\/jnumed.116.184218"},{"key":"2026071211371386754_j_raon-2024-0004_ref_018","doi-asserted-by":"crossref","unstructured":"Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. ESMO Guidelines Committee. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015; 26: v116\u201325. doi: 10.1093\/annonc\/mdv304","DOI":"10.1093\/annonc\/mdv304"},{"key":"2026071211371386754_j_raon-2024-0004_ref_019","doi-asserted-by":"crossref","unstructured":"Wang J, Weiss LM, Chang KL, Slovak ML, Gaal K, Forman SJ, et al. Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy. Cancer 2002; 94: 1522\u201331. doi: 10.1002\/cncr.10364","DOI":"10.1002\/cncr.10364"},{"key":"2026071211371386754_j_raon-2024-0004_ref_020","doi-asserted-by":"crossref","unstructured":"Salem P, Wolverson MK, Reimers HJ, Kudva GC. Complications of bone marrow biopsy. Br J Haematol 2003; 121: 821. doi: 10.1046\/j.1365-2141.2003.04328.x","DOI":"10.1046\/j.1365-2141.2003.04328.x"},{"key":"2026071211371386754_j_raon-2024-0004_ref_021","doi-asserted-by":"crossref","unstructured":"Vieira L, Pires A, Grilo A. Anxiety experienced by oncological patients who undergo 18F-FDG PET CT: a systematic review. Radiography 2021; 27: 1203\u201310. doi: 10.1016\/j.radi.2021.06.001","DOI":"10.1016\/j.radi.2021.06.001"},{"key":"2026071211371386754_j_raon-2024-0004_ref_022","doi-asserted-by":"crossref","unstructured":"Elamir Y, Elazab M, Owis AS, Elsayed HF. PET\/CT and bone marrow biopsy (BMB) in evaluating bone marrow in lymphoma. Egypt J Radiol Nucl Med 2020; 51: 201. doi: 10.1186\/s43055-020-00318-8","DOI":"10.1186\/s43055-020-00318-8"},{"key":"2026071211371386754_j_raon-2024-0004_ref_023","doi-asserted-by":"crossref","unstructured":"B\u00fcy\u00fck\u015fim\u015fek M, Kolsuz \u0130, Yeti\u015fir AE, Tohumcuo\u011flu M, O\u011ful A, Mirili C, et al. Performance of positron emission tomography-computed tomography and bone marrow biopsy in detecting bone marrow infiltration in lymphoma cases. Turk J Haematol 2020; 37: 220\u201325. doi: 10.4274\/tjh.galenos.2020.2019.0361","DOI":"10.4274\/tjh.galenos.2020.2019.0361"},{"key":"2026071211371386754_j_raon-2024-0004_ref_024","unstructured":"Pelosi E, Penna D, Douroukas A, Bell\u00f2 M, Amati A, Arena V, et al. Bone marrow disease detection with FDG-PET\/CT and bone marrow biopsy during the staging of malignant lymphoma: results from a large multicentre study. Q J Nucl Med Mol Imaging 2011; 55: 469\u201375. PMID: 21150862"},{"key":"2026071211371386754_j_raon-2024-0004_ref_025","doi-asserted-by":"crossref","unstructured":"Kandeel AA, Hussein M, Zidan L, Younis J, Edesa W, Alsayed Y. Diagnostic performance of 18F-2-fluoro-2-deoxy-D-glucose PET\/computerized tomography in identifying bone marrow infiltration in new patients with diffuse large B-cell lymphoma and Hodgkin lymphoma. Nucl Med Commun 2020; 41: 269\u201379. doi: 10.1097\/MNM.0000000000001139","DOI":"10.1097\/MNM.0000000000001139"},{"key":"2026071211371386754_j_raon-2024-0004_ref_026","doi-asserted-by":"crossref","unstructured":"Almaimani J, Tsoumpas C, Feltbower R, Polycarpou I. FDG PET\/CT versus bone marrow biopsy for diagnosis of bone marrow involvement in non-hodgkin lymphoma: a systematic review. Applied Sciences 2022; 12: 540. doi: 10.3390\/app12020540","DOI":"10.3390\/app12020540"},{"key":"2026071211371386754_j_raon-2024-0004_ref_027","doi-asserted-by":"crossref","unstructured":"Chang JM, Lee HJ, Goo JM, Lee HY, Lee JJ, Chung JK, et al. False positive and false negative FDG-PET scans in various thoracic diseases. Korean J Radiol 2006; 7: 57\u201369. doi: 10.3348\/kjr.2006.7.1.57","DOI":"10.3348\/kjr.2006.7.1.57"},{"key":"2026071211371386754_j_raon-2024-0004_ref_028","doi-asserted-by":"crossref","unstructured":"Aoki J, Watanabe H, Shinozaki T, Takagishi K, Ishijima H, Oya N, et al. FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology 2001; 219: 774\u20137.","DOI":"10.1148\/radiology.219.3.r01ma08774"},{"key":"2026071211371386754_j_raon-2024-0004_ref_029","doi-asserted-by":"crossref","unstructured":"Yao Z, Deng L, Xu-Monette ZY, Manyam GC, Jain P, Tzankov A, et al. Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia 2018; 32: 353\u201363. doi: 10.1038\/leu.2017.222.","DOI":"10.1038\/leu.2017.222"},{"key":"2026071211371386754_j_raon-2024-0004_ref_030","doi-asserted-by":"crossref","unstructured":"Alonso-\u00c1lvarez S, Alcoceba M, Garc\u00eda-\u00c1lvarez M, Blanco O, Rodr\u00edguez M, Baile M, et al. Biological features and prognostic impact of bone marrow infiltration in patients with diffuse large b-cell lymphoma. Cancers 2020; 12: 474. doi: 10.3390\/cancers12020474","DOI":"10.3390\/cancers12020474"},{"key":"2026071211371386754_j_raon-2024-0004_ref_031","doi-asserted-by":"crossref","unstructured":"Horvat M, Zadnik V, Ju\u017eni\u010d \u0160etina T, Bolte\u017ear L, Pahole Goli\u010dnik J, Novakovi\u0107 S, et al. Diffuse large B-cell lymphoma: 10 years\u2019 real-world clinical experience with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone. Oncol Lett 2018; 15: 3602\u20139. doi: 10.3892\/ol.2018.7774","DOI":"10.3892\/ol.2018.7774"}],"container-title":["Radiology and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/reference-global.com\/pdf\/10.2478\/raon-2024-0004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T23:56:26Z","timestamp":1783900586000},"score":1,"resource":{"primary":{"URL":"https:\/\/reference-global.com\/article\/10.2478\/raon-2024-0004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,21]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2,21]]},"published-print":{"date-parts":[[2024,3,1]]}},"alternative-id":["10.2478\/raon-2024-0004"],"URL":"https:\/\/doi.org\/10.2478\/raon-2024-0004","relation":{},"ISSN":["1581-3207"],"issn-type":[{"value":"1581-3207","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,21]]}}}